Flow Diagram of the Trial Selection Process

Slides:

Advertisements

Similar presentations

Trial profile Fox K et al. Lancet 2008;372:

Advertisements

FAME 2 year Objective:To investigate the 2-year outcome of PCI guided by FFR in patients with multivessel CAD. Study:Multicenter, single blind, randomized.

Update on the Medical Management of Acute Coronary Syndrome.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Coronary Artery Disease Angina Pectoris Unstable Angina Variant Angina Joseph D. Lynch, MD.

Cardio Investigations. Patients presenting with chest pain may be identified as having definite or possible angina from their history alone. Risk Factor.

Flow of Participants Through the Trial David J. A. Jenkin et al. JAMA 2008;300:

Ho PM, et al. JAMA 2009;301: Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

MENU ΣΤΕΦΑΝΙΑΙΑ ΝΟΣΟΣ ΣΕ ΔΙΑΒΗΤΙΚΟΥΣ ΚΑΙ ΗΛΙΚΙΩΜΕΝΟΥΣ.

4S: Scandinavian Simvastatin Survival Study

Baseline Characteristics of Patients Referred for Stress Myocardial Perfusion Testing by Erectile Function Classification James K. Min, et al, Arch Intern.

Flow Diagram of Identification of Randomized Trials for Inclusion Goran Bjelakovic, et al. JAMA. 2007;297:

Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: The thrombolysis in myocardial infarction risk score.

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Varespladib and Cardiovascular Events in Patients.

The SYMPHONY Trial Reference Reddan DN, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association Between Influenza Vaccination and Cardiovascular.

Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.

Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association Between Endoscopic vs Open Vein-Graft.

Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Public Reporting for Percutaneous.

Search strategy and results Amir Kashani, et al. Circulation. 2006;114:

Christopher P. Cannon, M. D. , Eugene Braunwald, M. D. , Carolyn H

Subgroup analyses for mortality after treatment with coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI). LAD, left anterior.

IABP-SHOCK II Score Stratifies Patient Risk in CS after AMI

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

The European Society of Cardiology Presented by Dr. Bo Lagerqvist

Clinical need for determination of vulnerable plaques

Impella 2.5® Device Is Associated with Improved Survival in AMICS

Baseline characteristics of patients

American College of Cardiology Presented by Dr. Stephan Windecker

Study Design Ketil Lunde, et al. N Engl J Med 2006;355:

Fewer PCIs After Public Reporting Changes in NY

Bjarne L. Nørgaard et al. JACC 2018;72:

Nat. Rev. Cardiol. doi: /nrcardio

Anticoagulation and Thrombosis Management

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

Characteristics of elderly patients prescribed statins after acute myocardial infarction (AMI) in Quebec, Ontario and British Columbia - Part I Zheng.

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Berger JS, et al. JAMA 2009;301:

Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care Marc Cohen, MD Mayo Clinic Proceedings

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

Nat. Rev. Cardiol. doi: /nrcardio

Study Participant Flow

(A) Meta-analysis of repeat revascularisation in randomised trials.

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:

Advantages of an early invasive approach in acute coronary syndromes

Adjunctive Therapies in the Treatment of Acute Coronary Syndromes

Forest plots of randomised controlled trials and propensity score matched studies examining outcomes between patients taking proton pump inhibitor (PPIs)

Baseline Characteristics of the Patients – Part I

Algorithm for the investigation of patients with elevated cardiac troponin concentrations in the context of an alternative acute illness. Algorithm for.

Characteristics of included studies

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

Flow diagram of Coronary Artery Bypass Graft-Acute Coronary Syndrome (CABG-ACS) trial. Flow diagram of Coronary Artery Bypass Graft-Acute Coronary Syndrome.

Additional benefit of PCSK9 inhibition in high risk patients after myocardial infarction A FOURIER subanalysis Primary endpoint: composite of CV death,

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

Baseline characteristics of study population

Result of coronary angiogram among patients with and without diabetes admitted with first-time acute coronary syndrome (a significant stenosis was defined.

Javier Escaned et al. JCIN 2018;11:

Increased Rehospitalization Rate After Coronary Bypass Operation for Acute Coronary Syndrome: A Prospective Study in 200 Patients Staffan Bjessmo, MD,

Performance of the Manchester Acute Coronary Syndromes decision rule with high-sensitivity cardiac troponin T (hs-cTnT) as the reference standard for the.

Performance of the Manchester Acute Coronary Syndromes decision rule in the validation study. Performance of the Manchester Acute Coronary Syndromes decision.

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.

Study flow chart and diagnosis at discharge from ED

Presentation transcript:

Flow Diagram of the Trial Selection Process ROXIS indicates the Roxithromycin in Patients with Acute Non–Q-Wave Coronary Syndromes trial R. Andraws et al. JAMA. 2005;293:2641-2647

Antibiotic Trials in Patients With Coronary Artery Disease R. Andraws et al. JAMA. 2005;293:2641-2647

Baseline Characteristics - Part I R. Andraws et al. JAMA. 2005;293:2641-2647

Baseline Characteristics - Part II R. Andraws et al. JAMA. 2005;293:2641-2647

Baseline Characteristics - Part III R. Andraws et al. JAMA. 2005;293:2641-2647

Effect of Antibiotic Treatment on Total Mortality R. Andraws et al. JAMA. 2005;293:2641-2647

Effect of Antibiotic Treatment on Myocardial Infarction R. Andraws et al. JAMA. 2005;293:2641-2647

Effect of Antibiotic Treatment on Acute Coronary Syndromes (Myocardial Infarction and Unstable Angina) R. Andraws et al. JAMA. 2005;293:2641-2647